Diabetes management in older people: a focus on cardiovascular risk reduction

References

• Meneilly GS, Tessier D. Diabetes in elderly adults. J Gerontol A Biol Sci Med Sci. 2001;56:M5–M13.
   PubMedGoogle Scholar
• Cowie C, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32:287–294.
   PubMed Web of Science ®Google Scholar
• Lim MA, Townsend RR. Arterial compliance in the elderly: its effect on blood pressure measurement and cardiovascular outcomes. Clin Geriatr Med. 2009;25:191–205.
   PubMed Web of Science ®Google Scholar
• McVeigh GE, Alen PB, Morgan DR, et al. Nitric oxide modulation of blood vessel tone identified by arterial wave form analysis. Clin Sci. 2001;100:387–393.
   PubMed Web of Science ®Google Scholar
• Carnethon MR, Biggs ML, Barzilay J, et al. Diabetes and coronary heart disease as risk factors for mortality in older adults. Am J Med. 2010;123:556.e1–556.e9.
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234.
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–2222.
   PubMed Web of Science ®Google Scholar
• Mueller T, Hinterreiter F, Luft C, et al. Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes. J Vasc Surg. 2014;59:1291–1299.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–1146.
   PubMed Web of Science ®Google Scholar
• Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016;4:537–547.
   PubMed Web of Science ®Google Scholar
• Davidson LE, Hudson R, Kilpatrick K, et al. Effects of exercise modality on insulin resistance and functional limitation in older adults. A randomized controlled trial. Arch Intern Med. 2009;169:122–131.
   PubMed Web of Science ®Google Scholar
• Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–1686.
   PubMed Web of Science ®Google Scholar
• Stewart KJ. Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. JAMA. 2002;288:1622–1631.
   PubMed Web of Science ®Google Scholar
• Rea TD, Heckbert SR, Kaplan RC, et al. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med. 2002;137:494–498.
   PubMed Web of Science ®Google Scholar
• Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380:807–814.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Ismail-Beigi F, et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet. 2014;384:1936–1941.
   PubMed Web of Science ®Google Scholar
• Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197–2206.
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Krumholz H, Soones T, et al. Polypharmacy in the aging patient: a review of glycemic control in older adults with type 2 diabetes. JAMA. 2016;315:1034–1045.
   PubMed Web of Science ®Google Scholar
• Lamanna C, Monami M, Marchionni N, et al. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13:221–228.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Goodman AM, The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541–549.
   PubMed Web of Science ®Google Scholar
• Chan JC, Tomlinson B, Critchley JA, et al. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care. 1993;16:1035–1038.
   PubMed Web of Science ®Google Scholar
• Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab. 2003;29(4 Pt 2):6S44–6S52.
   PubMed Web of Science ®Google Scholar
• Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6:395–402.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
   PubMed Web of Science ®Google Scholar
• Dargie HJ, Hildebrandt PR, Riegger GAJ, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol. 2007;49:1696–1704.
   PubMed Web of Science ®Google Scholar
• Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129–1136.
   PubMed Web of Science ®Google Scholar
• Mannucci E, Monami M, Lamanna C, et al. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2008;10:1221–1238.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–328.
   PubMed Web of Science ®Google Scholar
• Chang Y-C, Chuang L-M, Lin J-W, et al. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with type 2 diabetes: a nationwide cohort study. Diabet Med. 2015;32:1460–1469.
   PubMed Web of Science ®Google Scholar
• Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900–1908.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double blind trial. Lancet. 2015;385:2067–2076.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713.
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677–684.
   PubMed Web of Science ®Google Scholar
• Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276:1886–1892.
   PubMed Web of Science ®Google Scholar
• Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–68.
   PubMed Web of Science ®Google Scholar
• Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–1585.
   PubMed Web of Science ®Google Scholar
• Jerums G, Panagiotopoulos S, Ekinci E, et al. Cardiovascular outcomes with antihypertensive therapy in type 2 diabetes: an analysis of intervention trials. J Hum Hypertens. 2015;29:473–477.
   PubMed Web of Science ®Google Scholar
• Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717.
   PubMed Web of Science ®Google Scholar
• Remonti LR, Dias S, Leitão CB, et al. Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes – network meta-analysis of randomized trials. J Diabetes Complications. 2016;30(6):1192–1200. DOI:10.1016/j.jdiacomp.2016.04.020
   Google Scholar
• Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100:1254–1262.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother. 2010;11(16):2599–2607.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. The Cholesterol Treatment Trialists’ (CTT) Collaborators: efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
   PubMed Web of Science ®Google Scholar
• Neil HAW, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65–75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006;29:2378–2384.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.
   PubMed Web of Science ®Google Scholar
• Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis epidemiology, pathophysiology and management. JAMA. 2002;287:2570–2581.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860.
   PubMed Web of Science ®Google Scholar
• Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. Diabetes Care. 2010;22:1395–1402.
   Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393.
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving H-H, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591.
   PubMed Web of Science ®Google Scholar
• Sirois C, Moisan J, Poirier P, et al. Underuse of cardioprotective treatment by the elderly with type 2 diabetes. Diabetes Metab. 2008;34:169–176.
   PubMed Web of Science ®Google Scholar
• Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr. 2010;91:1123S–7S.
   PubMed Web of Science ®Google Scholar
• Tieland M, Dirks ML, van der Zwaluw N, et al. Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: a randomized, double-blind, placebo controlled trial. J Am Med Dir Assoc. 2012;13:713–719.
   PubMed Web of Science ®Google Scholar
• Rejeski WJ, Ip EH, Bertoni AG, et al. Life style change and mobility in obese adults with type 2 diabetes. N Engl J Med. 2012;366:1209–1217.
   PubMed Web of Science ®Google Scholar
• Valenzuela T. Efficacy of progressive resistance training interventions in older adults in nursing homes: a systematic review. J Am Med Dir Assoc. 2012;13:418–428.
   PubMed Web of Science ®Google Scholar
• de Ruijter W, Westendorp RGJ, Assendelft WJJ, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ. 2008;337:a3083. DOI:10.1136/bmj.a3083
   Google Scholar
• Kopple JD. The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. Am J Clin Nutr. 2005;81:1257–1266.
   PubMed Web of Science ®Google Scholar
• Vischer UM, Safar ME, Safar H, et al. Cardiometabolic determinants of mortality in a geriatric population: is there a “reverse metabolic syndrome”? Diabetes Metab. 2009;35:108–114.
   PubMed Web of Science ®Google Scholar
• Cox DJ, Kovatchev BP, Gonder-Frederick LA, et al. Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care. 2005;28:71–77.
   PubMed Web of Science ®Google Scholar
• Greco D, Pisciotta M, Gambina F, et al. Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol Diabetes. 2010;118:215–219.
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Ross JS, Miao Y, et al. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med. 2015;175:356–362.
   PubMed Web of Science ®Google Scholar
• Sussman J, Kerr EA, Saini SD, et al. Rates of deintensification of blood pressure and glycemic medication treatment based on levels of control and life expectancy in older patients with diabetes mellitus. JAMA Intern Med. 2015;175:1942–1949.
   PubMed Web of Science ®Google Scholar
• Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–1898.
   PubMed Web of Science ®Google Scholar
• Molander L, Lövheim H, Norman T, et al. Lower systolic blood pressure is associated with greater mortality in people aged 85 and older. J Am Geriatr Soc. 2008;56:1853–1859.
   PubMed Web of Science ®Google Scholar
• Mann JFE, Anderson C, Gao P, et al. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens. 2013;31:414–421.
   PubMed Web of Science ®Google Scholar
• Anum EA, Adera T. Hypercholesterolemia and coronary heart disease in the elderly: a meta-analysis. Ann Epidemiol. 2004;14:705–721.
   PubMed Web of Science ®Google Scholar
• Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+ year olds. Age and Ageing. 2010;39:674–680.
   PubMed Web of Science ®Google Scholar
• Sjoblom P, Tengblad A, Lofgren UB, et al. Can diabetes medication be reduced in elderly patients? An observational study of diabetes drug withdrawal in nursing home patients with tight glycaemic control. Dib Res Clin Pract. 2008;82:197–202.
   PubMed Web of Science ®Google Scholar
• Abdelhafiz AH, Chakravorty P, Gupta S, et al. Can hypoglycaemic medications be withdrawn in older people with type 2 diabetes? Int J Clin Pract. 2014;68:790–792.
   PubMedGoogle Scholar